Partial immunity and SARS-CoV-2 mutations

Science. 2021 Apr 23;372(6540):354. doi: 10.1126/science.abi4727.

Authors

William P Hanage¹, Colin A Russell²

Affiliations

¹ Department of Epidemiology, Harvard University T. H. Chan School of Public Health, Boston, MA 02115, USA. w.hanage@hsph.harvard.edu c.a.russell@amsterdamumc.nl.
² Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, Netherlands. w.hanage@hsph.harvard.edu c.a.russell@amsterdamumc.nl.

PMID: 33888632
DOI: 10.1126/science.abi4727

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Mutation
SARS-CoV-2*
Spike Glycoprotein, Coronavirus

Substances

COVID-19 Vaccines
Spike Glycoprotein, Coronavirus